ArGen-X BV, of Rotterdam, the Netherlands, signed a nonexclusive license agreement with Princeton, N.J.-based BioWa Inc...Selexis SA, of Geneva, signed a license agreement with CSL Ltd., of Melbourne, Australia, for preclinical development of a therapeutic antibody using Selexis's SUREtechnology Platform

Aslan Pharmaceuticals Pte Ltd., of Singapore, and Array BioPharma Inc., of Boulder, Colo., signed a license agreement to develop Array's HER2/EGFR inhibitor, ARRY-543, currently starting Phase II development for solid tumors

Optimer also has filed a marketing authorization application for fidaxomicin with the European Medicines Agency and has entered an exclusive collaboration and license agreement with Astellas Pharma Europe Ltd

Aslan Pharmaceuticals Pte Ltd., of Singapore, and Array BioPharma Inc., of Boulder, Colo., signed a license agreement to develop Array's HER2/EGFR inhibitor, ARRY-543, currently starting Phase II development for solid tumors

Vanda Pharmaceuticals Inc., of Rockville, Md., signed an exclusive license agreement with Probiomed SA de CV, a wholly owned unit of Mexico City-based Proquifin SA de CV, for the commercialization of schizophrenia drug Fanapt (iloperidone) in Mexico

Inovio Biomedical Corp., of Blue Bell, Pa., expanded its license agreement with the University of Pennsylvania, adding exclusive worldwide licenses for technology and intellectual property for DNA vaccines against pandemic influenza, Chikungunya and foot-and-mouth disease...The original 2007 license agreement gave Inovio exclusive worldwide rights to develop multiple DNA plasmids and constructs with the potential to treat or prevent HIV, HCV, HPV and influenza

Gilead Sciences Inc., of Foster City, Calif., entered a license agreement with New Brunswick, N.J.-based Johnson & Johnson subsidiary Tibotec Pharmaceuticals to develop and commercialize a fixed-dose combination of Gilead's Phase III boosting agent cobicistat and Tibotec's FDA-approved protease inhibitor Prezista (darunavir) for HIV

BioLineRx Ltd., of Jerusalem, signed a worldwide, exclusive license agreement with Yissum Research Development Co

BioLineRx Ltd., of Jerusalem, signed a worldwide, exclusive license agreement with Yissum Research Development Co...The assets would be acquired under a Chapter 11 bankruptcy proceeding, and would include royalty-bearing license agreements for certain cosmeceutical products marketed by third parties that employ Transdel delivery technology

Agenus Inc., of Lexington, Mass., announced that its wholly owned subsidiary Antigenics signed a license agreement with Integrated BioTherapeutics Inc., of Gaithersburg, Md., for the use of Antigenics' QS-21 Stimulon adjuvant in the development of a vaccine against Ebola and Marburg viruses

Nuron Biotech Inc., of Exton, Pa., secured an exclusive option and license agreement using London-based PolyTherics Ltd.'s site-specific TheraPEG pegylation technology to develop NU400, a long-acting version of Nuron's recombinant human interferon beta-1b (NU100) for multiple sclerosis

Debiopharm Group, of Lausanne, Switzerland, signed an exclusive, worldwide license agreement with Yale University for development and commercialization of Debio 1036 for autoimmune and inflammatory diseases...In other news, Sanofi-Aventis said that the company terminated its potential $375 million, July 2010 license agreement with Metabolex Inc., of Hayward, Calif., for diabetes drug SAR260093/MBX-2982, a GPR119 receptor agonist

Sanofi-Aventis SA, of Paris, said that the company terminated its potential $375 million, July 2010 license agreement with Metabolex Inc., of Hayward, Calif., for diabetes drug SAR260093/MBX-2982, a GPR119 receptor agonist. (See BioWorld Today, June 28, 2010

Debiopharm Group, of Lausanne, Switzerland, signed an exclusive, worldwide license agreement with Yale University for development and commercialization of Debio 1036 for autoimmune and inflammatory diseases

Affitech A/S, of Copenhagen, Denmark, inked a license agreement with Cancer Research Technology (CRT), the commercial arm of Cancer Research UK, granting the firm exclusive rights to a CRT patent application and know-how for developing and using therapeutic antibodies that recognize and block the function of CCR4, a protein found on certain tumors such as cervical and esophageal cancer

Affitech A/S, of Copenhagen, Denmark, inked a license agreement with Cancer Research Technology (CRT), the commercial arm of Cancer Research UK, granting the firm exclusive rights to a CRT patent application and know-how for developing and using therapeutic antibodies that recognize and block the function of CCR4, a protein found on certain tumors such as cervical and esophageal cancer

Karo Bio, of Huddinge, Sweden, entered a collaboration and license agreement with Alkem Laboratories Ltd., of Mumbai, India, giving Alkem exclusive rights to commercialize eprotirome in India and certain other markets in Asia-Pacific and Africa

The companies said they are negotiating a collaborative research and license agreement for research, development and commercialization of Diabecell in Japan and other Asian countries, excluding China where Living Cell has an existing deal with Jiangsu Aosaikang Pharmaceutical Co., of Nanjing, China

Forest has been assigned a license agreement between Warner Chilcott Co